Vidarabine
In clinical developmentAlso known as 9-beta-D-Arabinofuranosyladenine, 9-beta-D-arabinofuranosyl-9H-purin-6-amine, 9-beta-D-arabinofuranosyl-adenine, Spongoadenosine+2 more
9-beta-D-Arabinofuranosyladenine, 9-beta-D-arabinofuranosyl-9H-purin-6-amine, 9-beta-D-arabinofuranosyl-adenine, Spongoadenosine, Vira-A, Vidarabinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine3
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
- The Lancet. Oncology1
- Flinn IW2
- Goy A2
- Hill BT2
- Jacobson CA2
- Locke FL2
- McSweeney PA2
- Miklos DB2
- Munoz J2
- and the Institute of Clinical Microbiology1
- Banner MD Anderson Cancer Center1
- City of Hope National Medical Center1
- Cleveland Clinic Foundation1
- Colorado Blood Cancer Institute1
- Dana-Farber Cancer Institute1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 11 of the same disease areas as Vidarabine in the shared literature.
Studied across 11 of the same disease areas as Vidarabine in the shared literature.
Studied across 3 of the same disease areas as Vidarabine in the shared literature.
Studied across the same disease area as Vidarabine in the shared literature.
Studied across the same disease area as Vidarabine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials